SCHEMBL9976763

SCHEMBL9976763

c1ccc2cc(-c3ccc(-c4cc5c(cc(-c6ccc7ccccc7c6)c6cccnc65)c5ncccc45)cc3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.45
CYP19A1 P11511 1/20 0.45
CYP11B1 P15538 1/20 0.45
CYP11B2 P19099 1/20 0.45
CCR1 P32246 3/20 0.44
CCR8 P51685 3/20 0.44
KDM4E B2RXH2 2/20 0.44
LMNA P02545 2/20 0.44
GMNN O75496 1/20 0.44
TP53 P04637 1/20 0.44
HSP90AA1 P07900 1/20 0.44
MMP2 P08253 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
MAPT P10636 1/20 0.44
MMP9 P14780 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44
MMP8 P22894 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9976748 0.95 CCR1 (0.48) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL27934158 0.92 CCR1 (0.46) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL9976752 0.84 TOP1 (0.49) CCR1CCR8HSP90AA1MMP2NPC1
SCHEMBL15496959 0.84 CYP11B1 (0.42) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL12831011 0.83 HTR2B (0.34) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL28809041 0.83 ALDH1A1 (0.56) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL29720563 0.83 ALDH1A1 (0.56) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL12577950 0.83 CYP11B1 (0.38) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL12577892 0.83 GPR84 (0.39) CYP17A1CYP19A1CYP11B1CYP11B2CCR1
SCHEMBL14478694 0.82 ALDH1A1 (0.42) CYP17A1CYP19A1CYP11B1CYP11B2CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8877354-B2 Heterocyclic compound and organic light-emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-11-04 US disclosed
US-8877354-B2 Heterocyclic compound and organic light-emitting device using the same CANON KABUSHIKI KAISHA (JP) 2014-11-04 US disclosed
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-06-21 US disclosed
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME CANON KABUSHIKI KAISHA (JP) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120153270-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE SAME ORC3, CYP1A1, CRY1 CYP17A1 395/4885CYP19A1 14/4885CYP11B1 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.